Search This Blog

Monday, June 9, 2025

Universal Health Services at Goldman Sachs Conference

 On Monday, 09 June 2025, Universal Health Services (NYSE:UHS) shared its strategic plans at the Goldman Sachs 46th Annual Global Healthcare Conference. The discussion, led by CFO Steve Hilton, highlighted UHS’s transition into a post-COVID operational landscape, balancing growth opportunities with challenges such as labor costs and regulatory changes.

Key Takeaways

  • UHS is experiencing mid-single-digit revenue growth, driven by both price and volume increases.
  • Efforts are underway to stabilize labor costs and improve operational efficiency.
  • The company is expanding its hospital network, adding approximately 300 beds in both 2024 and 2025.
  • Behavioral health business aims to return to historical volume growth levels.
  • Regulatory changes, including potential impacts from DPP and ACA subsidies, are being closely monitored.

Financial Results

Acute Care:

  • Revenue growth is projected at 5-7%, with a midpoint of 6%.
  • Adjusted admission growth is targeted at 2.5-3.5%, with similar pricing growth.
  • Acute care margins are expected to return to pre-pandemic levels of 16-16.5% within 18-24 months.
  • West Henderson and D.C. hospitals are expected to be modestly EBITDA positive this year.

Behavioral Health:

  • Volume growth target is set at 2.5-3%.
  • Historical revenue growth remains in the mid-single digits.
  • EBITDA margins are currently at the upper end of the historical range, 22-23%.
  • Strong pricing continues to support the business.

Operational Updates

Acute Care:

  • Length of stay is currently 6-7% above baseline, with ongoing efforts to reduce it.
  • New hospitals are set to add approximately 300 beds in 2024 and another 300 in 2025.
  • Contractual pricing for acute care is seeing increases in the 4-5% range.

  • Behavioral Health:

  • The company is addressing staffing constraints to enhance bed utilization and patient volume.
  • 140 beds have been added in 2024, resuming growth paused during the pandemic.
  • There is an increased focus on outpatient services to capture a larger market share.

Future Outlook

  • UHS anticipates acute care margins to return to pre-COVID levels within 18-24 months.
  • In behavioral health, pricing is expected to moderate as volumes recover.
  • New hospitals are projected to achieve divisional average performance within 18-24 months.
  • The company plans to continue expanding its hospital network, with bed additions contributing to growth.
  • Long-term revenue growth is expected to stabilize in the 6-8% range, balancing pricing and volume.

Q&A Highlights

  • There is potential to further reduce the length of stay, enhancing efficiency and profitability.
  • UHS is optimistic about the terms of DPP in current legislative discussions.
  • The company has resumed bed additions after a pandemic-related pause.
  • The potential loss of enhanced ACA subsidies could have a $95 million impact.

In conclusion, Universal Health Services outlines a robust strategy for sustainable growth and margin expansion, focusing on efficiency and strategic investments. For more details, please refer to the full transcript below.

Full transcript - Goldman Sachs 46th Annual Global Healthcare Conference:


Viatris at Goldman Sachs Conference

 On Monday, 09 June 2025, Viatris Inc. (NASDAQ:VTRS) presented at the Goldman Sachs 46th Annual Global Healthcare Conference, outlining its strategic initiatives amidst operational challenges. The company’s CEO, Scott Smith, emphasized the strength of its base business and future growth prospects, despite ongoing manufacturing issues at its Indoor facility. Viatris is strategically pivoting towards innovative products while managing capital allocation through dividends and share buybacks.

Key Takeaways

  • Viatris has bought back over $300 million in shares as part of its capital allocation strategy.
  • The company faces a $500 million revenue impact in 2025 due to issues at its Indoor facility.
  • Viatris is focusing on innovative, patented products to drive future growth.
  • The company is conducting an enterprise-wide strategic review to optimize its cost structure.
  • Viatris is actively managing potential tariff impacts on its U.S. pharmaceutical supply chain.

Financial Results

  • Share Buybacks: Viatris has repurchased over $300 million in shares, balancing returns to shareholders with business development investments.
  • Revenue Composition: Currently, 60% of Viatris’s products are branded, with 40% being generic. Only 1% of its portfolio is patent protected.
  • Indoor Facility Impact: The company anticipates a $500 million revenue impact in 2025 due to Indoor facility issues, with $140 million already impacting Q1.

Operational Updates

  • Base Business Strength: Viatris has achieved consecutive quarters of operational revenue growth, excluding Indoor plant issues.
  • Manufacturing Network: The company operates 25-26 manufacturing plants, with 8.5 billion doses produced annually in the U.S.
  • Pipeline Progress: Positive Phase III readouts for Effexor in Japan, Zulane Low Dose, Meloxicam, and a dim light vision product highlight pipeline advancements.

  • Future Outlook

  • Strategic Direction: Viatris aims to increase its focus on patented innovative products by 2030, alongside its existing base business.
  • New Product Pipeline: Fast-acting Meloxicam is set for a filing by year-end, with potential fast-track approval. Selatogrel and Sonarimod studies are progressing with data expected by late 2026 and 2027, respectively.

Q&A Highlights

  • Tariffs: The company is assessing potential tariff impacts on its supply chain, particularly for low-margin generics.
  • MFN Executive Order: Minimal current impact expected, with future considerations for new patented products.
  • Meloxicam: Positive Phase III results show promise for commercialization in the acute pain market.

For further details, readers are encouraged to refer to the full transcript below.

Full transcript - Goldman Sachs 46th Annual Global Healthcare Conference:


Guardant Health at Goldman Sachs Conference

 On Monday, 09 June 2025, Guardant Health (NASDAQ:GH) presented at the Goldman Sachs 46th Annual Global Healthcare Conference. The company shared a strategic overview, highlighting its robust performance and plans for future growth. While Guardant Health’s innovative platform and market expansion were praised, the path to profitability remains a challenge with a target breakeven by 2028.

Key Takeaways

  • Guardant Health demonstrated strong performance in therapy selection, REVEAL (MRD), and SHIELD (screening).
  • Key achievements included FDA breakthrough designation and updates to NCCN guidelines.
  • The company aims for breakeven by 2028, focusing on reducing cash burn and increasing ASPs.
  • A science-first, patient-driven approach underpins its strategy, with a focus on biopharma partnerships.
  • Guardant Health is leveraging its first-mover advantage in the screening market.

Financial Results

Guardant Health discussed its financial trajectory, focusing on the impact of different product ASPs on revenue. The company is targeting profitability by 2028, with efforts to reduce cash burn year over year. Improvements in gross margin and ASP increases are key components of their financial strategy.

Operational Updates

The company highlighted its strong performance across therapy selection, REVEAL (MRD), and SHIELD (screening). Notable developments included the FDA’s breakthrough device designation for multi-cancer detection and updates to the NCCN guidelines for SHIELD. Guardant Health is also expanding into the tissue market with Guardant360 Tissue.

Future Outlook

Guardant Health expressed confidence in its growth trajectory, driven by product innovation and a strong commercial team. The company plans to leverage its first-mover advantage in the screening market and continue investing in sales and marketing while managing cash burn effectively.

Q&A Highlights

During the Q&A session, the competitive landscape and Guardant Health’s differentiation through its smart liquid biopsy platform were discussed. The company’s science-first, patient-driven approach and its capabilities in biopharma partnerships were emphasized as key to its sustained success.

In conclusion, Guardant Health remains optimistic about its strategic growth path. Readers are encouraged to refer to the full transcript for detailed insights.

Full transcript - Goldman Sachs 46th Annual Global Healthcare Conference: